259 related articles for article (PubMed ID: 33431157)
21. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
22. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.
Li X; Mukandavire C; Cucunubá ZM; Echeverria Londono S; Abbas K; Clapham HE; Jit M; Johnson HL; Papadopoulos T; Vynnycky E; Brisson M; Carter ED; Clark A; de Villiers MJ; Eilertson K; Ferrari MJ; Gamkrelidze I; Gaythorpe KAM; Grassly NC; Hallett TB; Hinsley W; Jackson ML; Jean K; Karachaliou A; Klepac P; Lessler J; Li X; Moore SM; Nayagam S; Nguyen DM; Razavi H; Razavi-Shearer D; Resch S; Sanderson C; Sweet S; Sy S; Tam Y; Tanvir H; Tran QM; Trotter CL; Truelove S; van Zandvoort K; Verguet S; Walker N; Winter A; Woodruff K; Ferguson NM; Garske T;
Lancet; 2021 Jan; 397(10272):398-408. PubMed ID: 33516338
[TBL] [Abstract][Full Text] [Related]
23. Effects of geographic and economic heterogeneity on rotavirus diarrhea burden and vaccination impact and cost-effectiveness in the Lao People's Democratic Republic.
Rheingans R; Anderson JD; Bagamian KH; Pecenka CJ
Vaccine; 2018 Dec; 36(51):7868-7877. PubMed ID: 30007827
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review.
Ozawa S; Mirelman A; Stack ML; Walker DG; Levine OS
Vaccine; 2012 Dec; 31(1):96-108. PubMed ID: 23142307
[TBL] [Abstract][Full Text] [Related]
25. Monitoring what governments "give for" and "spend on" vaccine procurement: Vaccine Procurement Assistance and Vaccine Procurement Baseline.
Nelson EA; Bloom DE; Mahoney RT
PLoS One; 2014; 9(2):e89593. PubMed ID: 24586899
[TBL] [Abstract][Full Text] [Related]
26. Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.
Rheingans R; Atherly D; Anderson J
Vaccine; 2012 Apr; 30 Suppl 1():A15-23. PubMed ID: 22520124
[TBL] [Abstract][Full Text] [Related]
27. Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018.
Jit M
Value Health; 2021 Jan; 24(1):61-66. PubMed ID: 33431154
[TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
[TBL] [Abstract][Full Text] [Related]
29. Funding gap for immunization across 94 low- and middle-income countries.
Ozawa S; Grewal S; Portnoy A; Sinha A; Arilotta R; Stack ML; Brenzel L
Vaccine; 2016 Dec; 34(50):6408-6416. PubMed ID: 28029541
[TBL] [Abstract][Full Text] [Related]
30. How much does it cost to get a dose of vaccine to the service delivery location? Empirical evidence from Vietnam's Expanded Program on Immunization.
Mvundura M; Kien VD; Nga NT; Robertson J; Cuong NV; Tung HT; Hong DT; Levin C
Vaccine; 2014 Feb; 32(7):834-8. PubMed ID: 24370713
[TBL] [Abstract][Full Text] [Related]
31. The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries.
Chang AY; Riumallo-Herl C; Perales NA; Clark S; Clark A; Constenla D; Garske T; Jackson ML; Jean K; Jit M; Jones EO; Li X; Suraratdecha C; Bullock O; Johnson H; Brenzel L; Verguet S
Health Aff (Millwood); 2018 Feb; 37(2):316-324. PubMed ID: 29401021
[TBL] [Abstract][Full Text] [Related]
32. The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade.
Lindstrand A; Cherian T; Chang-Blanc D; Feikin D; O'Brien KL
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S452-S467. PubMed ID: 34590130
[TBL] [Abstract][Full Text] [Related]
33. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
Constenla D; Liu T
Vaccine; 2019 Dec; 37(52):7547-7559. PubMed ID: 31607600
[TBL] [Abstract][Full Text] [Related]
34. Systematic review of the incremental costs of interventions that increase immunization coverage.
Ozawa S; Yemeke TT; Thompson KM
Vaccine; 2018 Jun; 36(25):3641-3649. PubMed ID: 29754699
[TBL] [Abstract][Full Text] [Related]
35. Tracking donor funding towards achieving the Global Vaccine Action Plan (GVAP) goals: A landscape analysis (1990-2016).
Ikilezi G; Zlavog B; Augusto OJ; Sherr K; Lim SS; Dieleman JL
Vaccine; 2018 Nov; 36(49):7487-7495. PubMed ID: 30366804
[TBL] [Abstract][Full Text] [Related]
36. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
[TBL] [Abstract][Full Text] [Related]
37. Stakeholders' perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: a mixed methods study.
van der Putten IM; Evers SM; Deogaonkar R; Jit M; Hutubessy RC
BMC Public Health; 2015 Apr; 15():356. PubMed ID: 25881178
[TBL] [Abstract][Full Text] [Related]
38. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study.
Savinkina A; Bilinski A; Fitzpatrick M; Paltiel AD; Rizvi Z; Salomon J; Thornhill T; Gonsalves G
BMJ Open; 2022 Sep; 12(9):e061752. PubMed ID: 36100306
[TBL] [Abstract][Full Text] [Related]
39. Charting the evolution of approaches employed by the Global Alliance for Vaccines and Immunizations (GAVI) to address inequities in access to immunization: a systematic qualitative review of GAVI policies, strategies and resource allocation mechanisms through an equity lens (1999-2014).
Gandhi G
BMC Public Health; 2015 Nov; 15():1198. PubMed ID: 26621528
[TBL] [Abstract][Full Text] [Related]
40. Making the leap into the next generation: A commentary on how Gavi, the Vaccine Alliance is supporting countries' supply chain transformations in 2016-2020.
Brooks A; Habimana D; Huckerby G
Vaccine; 2017 Apr; 35(17):2110-2114. PubMed ID: 28364917
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
